Article

C. albicans Flu1 mediated efflux of salivary Histatin 5 reduces its cytosolic concentration and fungicidal activity.

From the Department of Oral Biology University at Buffalo, Buffalo, New York 14214.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.57). 02/2013; DOI: 10.1128/AAC.02295-12
Source: PubMed

ABSTRACT Histatin 5 is a salivary human antimicrobial peptide that is toxic to the opportunistic yeast Candida albicans. Fungicial activity of Hst 5 requires intracellular translocation and accumulation to a threshold concentration for it to disrupt cellular processes. Previously we observed that total cytosolic levels of Hst 5 were gradually reduced from intact cells, suggesting that C. albicans possesses a transport mechanism for efflux of Hst 5. Since we identified C. albicans polyamine transporters responsible for Hst 5 uptake, we hypothesized that one or more polyamine efflux transporters may be involved in the efflux of Hst 5. C. albicans FLU1 and TPO2 were found to be the closest homologs of S. cerevisiae TPO1 that encodes a major spermidine efflux transporter, indicating the products of these two genes may be involved in efflux of Hst 5. We found flu1Δ/Δ cells, but not tpo2Δ/Δ cells, had significant reduction in their rate of Hst 5 efflux, and had significantly higher cytoplasmic Hst 5 and Hst 5 susceptibility compared to wild type. We also found that flu1Δ/Δ cells had reduced biofilm formation compared to wild-type cells in the presence of Hst 5. Transcriptional levels of FLU1 were not altered over the course of treatment with Hst 5; therefore Hst 5 is not likely to induce FLU1 gene over-expression as a potential mechanism of resistance. Thus Flu1, but not Tpo2, mediates efflux of Hst 5 and is responsible for reduction of its toxicity in C. albicans.

0 Bookmarks
 · 
98 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Azoles have consistently been recognized as the mainstays of antifungal drugs, amongst which ergosterol prevails as an integral component of fungal plasma membrane. It is most commonly produced via demethylation of lanosterol by the cytochrome P450-dependent enzyme lanosterol 14α-demethylase. Azoles exert their antifungal activities via binding to lanosterol 14 α-demethylase and thereby preventing the demethylation of lanosterol. This leads to the depletion of demethylated lanosterol (ergosterol) with the concomitant accumulation of methylated sterol precursors (lanosterol, 4,14-dimethylzymosterol, and 24-methylenedihydrolanosterol) and deterioration of the membrane integrity, resulting in fungal growth inhibition. Resistance to azoles is a concern, particularly during the long-term treatment of fungus mediated cellular complications. To combat azole resistance and to extend the spectrum of treatable pathogens, the development of novel and more potent azoles, with alteration in active sites has attracted worldwide scientific attention. With such an insight, this review focuses on antifungal potentials of azole compounds with an emphasis on the corresponding drug resistance episodes complemented with novel strategies for the development of new generation of azole compounds.
    The Natural Products Journal. 01/2014; 4(2).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antimicrobial peptides (AMPs) are key elements of innate immunity, which can directly kill multiple bacterial, viral and fungal pathogens. The medically important fungus Candida albicans colonizes different host niches as part of the normal human microbiota. Proliferation of C. albicans is regulated through a complex balance of host immune defense mechanisms and fungal responses. Expression of AMPs against pathogenic fungi is differentially regulated and initiated by interactions of a variety of fungal pathogen-associated molecular patterns (PAMPs) with pattern recognition receptors (PRRs) on human cells. Inflammatory signaling and other environmental stimuli are also essential to control fungal proliferation and to prevent parasitism. To persist in the host, C. albicans has developed a three-phase AMP evasion strategy including secretion of peptide effectors, AMP efflux pumps and regulation of signaling pathways. These mechanisms prevent C. albicans from the antifungal activity of the major AMP classes including cathelicidins, histatins and defensins leading to a basal resistance. This review summarizes human AMP attack and C. albicans resistance mechanisms, as well as current developments in the use of AMPs as antifungals.
    Eukaryotic Cell 06/2014; · 3.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Candida albicans is a major fungal pathogen in humans. Antimicrobial peptides (AMPs) are critical components of the innate immune response in vertebrates and represent the first line of defense against microbial infection. LL-37 is the only member of the human family of cathelicidin AMPs and is commonly expressed by various tissues and cells, including surfaces of epithelia. The candidacidal effects of LL-37 have been well documented, but the mechanisms by which LL-37 kills C. albicans are not completely understood. In this study, we examined the effects of LL-37 on cell wall and cellular responses in C. albicans. Using transmission electron microscopy, carbohydrate analyses, and staining for β-1,3-glucan, changing of C. albicans cell wall integrity was detected upon LL-37 treatment. In addition, LL-37 also affected cell wall architecture of the pathogen. Finally, DNA microarray analysis and quantitative PCR demonstrated that sub-lethal concentrations of LL-37 modulated the expression of genes with a variety of functions, including transporters, regulators for biological processes, response to stress or chemical stimulus, and pathogenesis. Together, LL-37 induces complex responses in C. albicans, making LL-37 a promising candidate for use as a therapeutic agent against fungal infections.
    The Journal of Microbiology 05/2014; · 1.53 Impact Factor

Full-text

Download
52 Downloads
Available from
May 23, 2014